<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Second-trimester pregnancy termination: Induction (medication) termination</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Second-trimester pregnancy termination: Induction (medication) termination</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Second-trimester pregnancy termination: Induction (medication) termination</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cassing Hammond, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jody Steinauer, MD, MAS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H8856878"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Second-trimester pregnancy termination may be performed with medication or surgery. Surgical termination, or dilation and evacuation (D&amp;E), requires dilating the cervix followed by surgical extraction of products of conception. Medication termination, or induction abortion, involves the administration of medication through one of a variety of routes to induce labor and deliver the fetus. Both methods are safe and effective, and each offers different advantages and disadvantages.</p><p>Patients may choose medication abortion if they prefer more awareness of the termination process, if they prefer an intact fetus, or if they want to avoid surgery. An intact fetus may be desirable if the patient desires to hold the fetus or, in cases of fetal anomalies, if an intact fetus is beneficial for a morphologic evaluation. In some health care settings, there is more access to second-trimester induction abortion than surgical abortion.</p><p>Second-trimester induction termination is reviewed here. An overview of second-trimester pregnancy termination and the technique for surgical abortion are discussed separately. First-trimester medication abortion is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination"</a> and  <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion"</a>.)</p><p class="headingAnchor" id="H8857844"><span class="h1">PREPROCEDURE PREPARATION</span><span class="headingEndMark"> — </span>Patients who desire second-trimester induction termination require preoperative evaluation to establish gestational age, assess general medical status, and identify any medical factors that may impact the choice of induction versus surgical termination. Many of the medical factors favoring medical abortion are "provider-dependent," in that they derive from a specific provider's skill in a particular situation.</p><p>Choice of procedure is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Choosing dilation and evacuation versus induction termination'</a>.)</p><p>Laws regarding abortion vary by country and by state in the United States. Most states restrict abortion after viability, although the definition of viability varies by state and maternal-fetal exemptions that countermand the viability statute vary by state. Clinicians offering abortion must be familiar with restrictions in their own locality.</p><p class="headingAnchor" id="H49655631"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>The role of laboratory testing for hemoglobin or hematocrit, Rh typing (and administration of Rhogam to Rh-negative individuals), and chlamydia and/or gonorrhea is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p class="headingAnchor" id="H4801490"><span class="h2">Prophylactic antibiotics</span><span class="headingEndMark"> — </span>Prophylactic antibiotics are not typically advised for second-trimester medication abortion. The Society of Family Planning (SFP) advises that prophylactic antibiotics may lower the risk of serious infection but advises against universal use [<a href="#rid1">1</a>]. (See <a class="local">'Infection'</a> below.)</p><p>The issue of antibiotic prophylaxis is similar for first-trimester medication abortion, which is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Limited role of prophylactic antibiotics'</a>.)</p><p class="headingAnchor" id="H8857850"><span class="h2">Cervical dilation</span><span class="headingEndMark"> — </span>There is no evidence that osmotic cervical dilation facilitates induction when using modern prostaglandin (PG) analogs [<a href="#rid2">2,3</a>]. Special "precervical ripening" is no longer indicated during the second trimester prior to induction abortion.</p><p>In a randomized trial including 347 patients undergoing medical termination of pregnancy between 15 0/7 and 27 6/7 weeks gestation, those receiving cervical preparation plus <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> compared with misoprostol alone had similar induction-to-abortion intervals; complication rates were also similar between groups [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H26605275"><span class="h2">Induced fetal demise</span><span class="headingEndMark"> — </span>Clinicians may induce demise prior to abortion either to facilitate the abortion procedure or to prevent live birth. SFP 2010 guidelines advise that induction of fetal demise prior to medical abortion might shorten induction-to-abortion interval, particularly if <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> (KCl) is utilized, though this is based on one small retrospective study using a PGE2 regimen [<a href="#rid5">5</a>]. More information is needed regarding the impact of different feticidal regimens on induction-to-abortion intervals among patients undergoing <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> termination.</p><p>To induce fetal demise, there are several options, including intracardiac KCl or intrafetal and intraamniotic <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>.</p><p>Induced fetal demise is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6819.html" rel="external">"Induced fetal demise"</a>.)</p><p class="headingAnchor" id="H8857856"><span class="h2">Anesthesia</span><span class="headingEndMark"> — </span>Patients undergoing medical induction can receive analgesia or anesthesia similar to that used for obstetric labor induction. Intermittent narcotic administration suffices for some patients, while others desire epidural anesthesia since this completely eliminates pain during more prolonged inductions. (See  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery"</a>.)</p><p class="headingAnchor" id="H8857868"><span class="h1">PROTOCOL</span><span class="headingEndMark"> — </span>Current protocols for second-trimester induction abortion typically include a prostaglandin (PG), usually <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, and may utilize <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> or <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>.</p><p class="headingAnchor" id="H2215685"><span class="h2">Type of prostaglandin</span><span class="headingEndMark"> — </span>Instillation abortion with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or urea has now been largely abandoned due to risks such as hypernatremia, coagulopathy, and hemorrhage [<a href="#rid6">6,7</a>]. In comparison with current methods of labor induction abortion (typically with <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>), randomized trial data show that instillation abortion results in longer induction times and higher rates of both blood transfusion and retained placenta [<a href="#rid7">7</a>].</p><p><a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">Oxytocin</a>, the most commonly used induction agent at later gestational ages, fails to induce labor as effectively as other single-agent therapies at midtrimester because the uterus has relatively fewer oxytocin receptors at less than 20 weeks of gestation. Oxytocin is associated with longer induction-abortion intervals than newer methods, as well as higher risks of side effects such as postpartum hemorrhage and even water intoxication [<a href="#rid8">8,9</a>]. Patients desiring medical abortion in the second trimester now have safer, more effective options, utilizing PG agents either alone or in combination with progesterone antagonists.</p><p>Several PG agents have been used to induce abortion:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> and gemeprost, both PGE1 analogs, are the most common medications used for induction abortion.</p><p></p><p class="bulletIndent1">Comparative studies have found that both <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> and gemeprost induce labor more effectively and with fewer side effects than other PGs (eg, carboprost, sulprostone) and single-agent <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> or oxytocin in combination with other types of PGs [<a href="#rid10">10-14</a>]. Both misoprostol and gemeprost induce labor at a variety of gestational ages [<a href="#rid15">15</a>]. The dose decreases as pregnancy advances because the uterus becomes more sensitive to PG with decreasing dose requirements as pregnancy advances.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> is typically the preferred agent due to lower rates of certain adverse effects and complications and based on practical considerations. Gemeprost and misoprostol have been found to have similar efficacy in randomized trials [<a href="#rid16">16-20</a>]. As an example, in one trial of 81 patients between 12 to 25 weeks of gestation, pregnancy termination with misoprostol (200 mcg every 12 hours) compared with gemeprost (1 mg every three hours) resulted in a significantly higher rate of complete abortion (61 versus 32 percent) but a longer induction-to-abortion interval (27.8 versus 14.5 hours). The mean blood loss was significantly lower in the misoprostol group. Patients treated with misoprostol had fewer adverse effects (eg, nausea, vomiting).</p><p></p><p class="bulletIndent1">The advantages of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> in comparison with gemeprost are reduced need for narcotic analgesia, less frequent need for surgical evacuation of the uterus, more routes of administration, is less expensive, and does not require refrigeration [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Carboprost, a PGF2alpha analog, results in more systemic side effects than PGE analogs [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sulprostone, a PGE2 analog, has fallen out of favor because it has been associated with myocardial infarction [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H2215691"><span class="h2">Route and regimen</span><span class="headingEndMark"> — </span>The route of administration, dose, and dosing interval of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> vary across protocols. There are limited high-quality data to establish the optimal protocol. In general, misoprostol administered by the buccal route has been found to have higher bioavailability than oral and with fewer adverse effects. Sublingual administration has similar efficacy to vaginal dosing. However, for first-trimester medication abortion, many experts advise avoiding vaginal administration due to concerns regarding infection. A systematic review of randomized trials found that the vaginal route was preferable although, among multiparous patients, sublingual administration appeared equally effective [<a href="#rid20">20</a>]. A subsequent randomized trial found that vaginal or sublingual dosing was associated with a shorter time to induction completion than oral dosing [<a href="#rid22">22</a>].</p><p>General principles of the dose, route of administration, and timing of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5434.html" rel="external">"Misoprostol as a single agent for medical termination of pregnancy", section on 'Drug administration'</a> and  <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Misoprostol'</a>.)</p><p>For the second trimester, the dose of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> ranges from 200 to 800 mcg. In regimens using misoprostol or gemeprost alone, median induction-to-abortion intervals are approximately 12 to 16 hours [<a href="#rid23">23</a>]. The abortion time interval is decreased with more frequent dosing. Two randomized trials demonstrated a significantly shorter induction time with vaginal administration of misoprostol 400 mcg every three hours compared with every six hours, without a significant increase in side effects [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H2215715"><span class="h3">Use of mifepristone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a> is an antiprogestin that competitively blocks both progesterone and glucocorticoid receptors. By opposing the activity of progesterone, mifepristone elicits a variety of effects that make the uterus more susceptible to abortion. These effects include cervical dilation, decidual necrosis, increased endogenous PG production, and increasing uterine sensitivity to exogenously administered PG. Mifepristone administration gradually elicits a fivefold increase in sensitivity to PG 24 to 48 hours after its administration [<a href="#rid26">26</a>]. The synergy between mifepristone and PG permits greater efficacy of PG at lower doses, potentially minimizing side effects [<a href="#rid27">27</a>].</p><p><a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> have been consistently found to be safe and effective in second-trimester induction abortion [<a href="#rid11">11,23,28</a>]. Mifepristone used in combination with misoprostol is the most effective method of inducing delivery in the second trimester [<a href="#rid29">29</a>]. Many different regimens utilizing mifepristone and misoprostol, alone or in combination, result in fetal expulsion within 24 hours during more than 90 percent of inductions [<a href="#rid30">30,31</a>]. In our practice, we begin inductions 24 hours after mifepristone administration, but we advise practitioners that beginning inductions within 12 hours is also safe and effective [<a href="#rid32">32</a>]. Certainly, providers have considerable latitude to accommodate patients' personal needs and the availability of induction services without fear of compromising safety.</p><p>The World Health Organization (WHO), American College of Obstetricians and Gynecologists (ACOG), Society of Family Planning (SFP), and Royal College of Obstetricians and Gynaecologists (RCOG) recommend regimens in which <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> precedes use of either <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> or gemeprost [<a href="#rid30">30,33-35</a>].</p><p>Use of <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> followed by <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> compared with mifepristone followed by <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> was compared in one randomized trial that found no significant difference in success rate (100 versus 96 percent). Time to fetal expulsion was longer in the oxytocin group (11.3 versus 7.0 hours), but the rate of fever and shivers was lower [<a href="#rid8">8</a>].</p><p>A systematic review analyzed results from 20 randomized trials and nine observational studies [<a href="#rid36">36</a>]. Pooled data demonstrated that administration of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> 12 to 24 hours after <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> modestly increased induction-abortion intervals by one to two hours. The overall abortion times, the time from administration of mifepristone to delivery, were substantially lower, though primarily because practitioners started inductions earlier. Another study compared a regimen that initiated mifepristone at the same time as misoprostol with a regimen in which misoprostol began 24 hours later. Although taking both medicines simultaneously decreased efficacy at 24 hours and resulted in increased total use of misoprostol, the overall time of the abortion process and the number of clinic visits were reduced [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H2215709"><span class="h3">Medical society protocols</span><span class="headingEndMark"> — </span>ACOG recommends the following protocols for second-trimester induction abortion [<a href="#rid33">33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a> 200 mg, administered orally, followed by:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> 800 mcg, administered vaginally, followed by 400 mcg, administered vaginally or sublingually every three hours for up to a maximum of five doses.</p><p></p><p class="bulletIndent2"><strong>Or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> 400 mcg, administered buccally every three hours for up to a maximum of five doses also may be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> is not available:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> 400 mcg, administered vaginally or sublingually every three hours for up to five doses. Vaginal dose is superior to sublingual dose for nulliparous patients.</p><p></p><p class="bulletIndent2"><strong>Or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A vaginal loading dose of 600 to 800 mcg of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, followed by 400 mcg administered vaginally or sublingually every three hours may be more effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> is not available:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">Oxytocin</a> 20 to 100 units, infused intravenously over three hours, followed by one hour without oxytocin to allow diuresis. Oxytocin dose may be slowly increased to a maximum of 300 units over three hours.</p><p></p><p>RCOG recommends 400 mcg of vaginal <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> every three hours, up to five doses, in pregnancies between 13 and 22 weeks [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H899248805"><span class="h3">Our practice</span><span class="headingEndMark"> — </span>In our practice, we administer <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> 24 hours before induction with <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> or other agents; shorter intervals are acceptable in some situations (eg, patient preference).</p><p class="bulletIndent1"><span class="glyph">●</span>If cervical dilation occurs but the patient does not deliver after five doses of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, we continue with additional doses of misoprostol until the fetus delivers. While the medical society protocols do not provide specific instruction on how to proceed in this situation, our practice is based on a retrospective study in which 17 percent of patients undergoing medical induction between 14 and 24 weeks required more than five doses of misoprostol; 60 percent of those patients (47 patients) required one or two additional doses prior to delivery of the fetus, and the maximum dose required was 12 [<a href="#rid38">38</a>]. Complication rates (eg, chorioamnionitis, postpartum hemorrhage, retained placenta) were similar among those who received ≤5 versus ≥6 misoprostol tablets. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, if cervical dilation does <strong>not</strong> occur after five doses of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue induction and restart the process with <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> after 12 to 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proceed with cervical preparation (eg, osmotic dilators, intracervical Foley balloon) followed by either administration of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> or <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>. (See  <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening", section on 'Balloon catheter'</a> and  <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening", section on 'Hygroscopic dilators'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer a higher dose of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> (up to 800 mcg vaginally) followed by lower doses. (See <a class="local">'Medical society protocols'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Switch induction agents and try <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a>. (See <a class="local">'Medical society protocols'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Convert to a surgical abortion if cervical dilation is adequate and a skilled provider is available.</p><p></p><p>We do not change our practice for patients with a prior hysterotomy (eg, cesarean birth, myomectomy). While these patients are at risk of uterine scar dehiscence, there is no evidence to support deviating from the ACOG/RCOG protocols. There is no evidence justifying alteration of medical induction regimens among patients with scarred uteri.</p><p>Termination after 23 weeks is not common in the United States, and an optimal regimen has not been established. When pregnancy termination is performed at ≥24 weeks, the indication is generally a fetal anomaly. For gestational ages 24 to 28 weeks, the SFP has published a systematic review and guidelines for pregnancy termination from 24 to 28 weeks; these include data and recommendations for pregnancy termination and labor induction for fetal demise [<a href="#rid39">39</a>]. For <a class="drug drug_general" data-topicid="114085" href="/z/d/drug information/114085.html" rel="external">mifepristone-misoprostol</a> regimens, seven observational studies were included and showed that a dosing regimen of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> 200 mcg or 400 mcg every four hours is associated with 24-hour expulsion rates of 80 to 97 percent, with mean expulsion times ranging from 8.5 to 13.6 hours. The SFP advised that <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> 200 mg or 600 mg be followed by misoprostol 36 to 48 hours later. </p><p>Misoprostol-only regimens for this gestational age range are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5434.html" rel="external">"Misoprostol as a single agent for medical termination of pregnancy", section on 'Accepted regimens'</a>.)</p><p class="headingAnchor" id="H2849813062"><span class="h2">Use of other medications</span><span class="headingEndMark"> — </span>There is variation in the approach to second-trimester abortion across medical settings. In China, approximately 7.63 million abortions were performed in 2007 [<a href="#rid40">40</a>]. The most common method of second-trimester abortion in China has been intraamniotic injection of ethacridine lactate, a dye with antiseptic properties. A systematic review of 15 randomized trials conducted in China evaluated <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> combined with <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> versus intraamniotic injection of ethacridine lactate and found that mifepristone/misoprostol has lower failures rates (2 to 6 percent versus 7 to 21 percent, risk ratio 0.37, 95% CI 0.17-0.80) and shorter time of labor (an average of 1.9 hours shorter). More gastrointestinal side effects occurred in the mifepristone/misoprostol group, but cervical injury was more frequent in the ethacridine lactate group.</p><p class="headingAnchor" id="H8857874"><span class="h1">OUTCOME AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Second-trimester surgical abortion is a safe and effective procedure. Most terminations are completed as inductions, but some patients require a surgical procedure for a retained placenta. In addition to retained products of conception, potential complications include uterine rupture, cervical laceration, hemorrhage, and infection.</p><p class="headingAnchor" id="H26605106"><span class="h2">Incomplete abortion</span><span class="headingEndMark"> — </span>Incomplete abortion is more common in second-trimester induction abortion than in surgical abortion (1 to 12.5 versus &lt;1 percent) [<a href="#rid33">33,41-43</a>]. </p><p class="headingAnchor" id="H8857880"><span class="h2">Retained placenta</span><span class="headingEndMark"> — </span>In induction procedures with <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, 2 to 10 percent of patients have a retained placenta [<a href="#rid23">23,44,45</a>]. Induction protocols that include misoprostol inductions less commonly require surgical intervention for delivery of the placenta than induction with other agents, though rates of retained placenta are higher for all medical methods compared with dilation and evacuation (D&amp;E) [<a href="#rid41">41,42,46</a>].</p><p>Traditionally, in an induction abortion, clinicians have performed curettage if the placenta remained undelivered 30 to 120 minutes following delivery of the fetus. This is based upon reports regarding a technique that is now used infrequently, hyperosmolar <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and prostaglandin E2 (PGE2), which was associated with higher rates of complications with an increasing interval from the delivery of the fetus to the placenta [<a href="#rid47">47,48</a>]. With <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> inductions, some data suggest that waiting for up to four hours is acceptable. As an example, in one retrospective study of 233 patients who underwent second-trimester induction with misoprostol, 59 percent of placentas delivered within one hour of fetal expulsion. The overall rate of surgical intervention for retained placenta was 6 percent, and 11 of 14 surgical procedures were performed to expedite hospital discharge [<a href="#rid49">49</a>]. An interval of four or more hours for the delivery of the placenta was not associated with increased morbidity.</p><p>As a result of this study for hemodynamically stable patients, we manage delivery of the placenta expectantly for four hours after delivery of the fetus before intervening to remove the placenta.</p><p class="headingAnchor" id="H8857886"><span class="h2">Uterine rupture</span><span class="headingEndMark"> — </span>Uterine rupture can occur in patients with a scarred or unscarred uterus [<a href="#rid50">50</a>]. In a systematic review of second-trimester abortion with <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, the risk of uterine rupture among patients with prior cesarean birth was 0.28 percent, whereas the risk in patients without prior cesarean was 0.04 percent [<a href="#rid51">51</a>]. The Society for Family Planning (SFP) in the United States supports second-trimester induction abortion in patients with prior cesarean birth [<a href="#rid30">30</a>]. No studies have evaluated the safety of medical abortion among patients with uterine scarring secondary to prior myomectomy or surgery for correction of müllerian uterine anomalies.</p><p class="headingAnchor" id="H8857892"><span class="h2">Cervical laceration</span><span class="headingEndMark"> — </span>Cervical laceration may occur in either induction or surgical abortion. (See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation", section on 'Cervical laceration'</a>.)</p><p class="headingAnchor" id="H8857898"><span class="h2">Infection</span><span class="headingEndMark"> — </span>The medications used for induction abortion, particularly <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, often result in pyrexia, which makes it difficult to evaluate the rate of infection. A literature review by the SFP reported a 1 to 3 percent incidence of infection, not solely pyrexia, following second-trimester medication abortion [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H8857970"><span class="h2">Hemorrhage</span><span class="headingEndMark"> — </span>Hemorrhage resulting in transfusion complicates less than 1 percent of induction terminations. The risk of hemorrhage increases with gestational age and duration of induction. Common causes include retained products of conception, uterine atony, and trauma to the lower genital tract [<a href="#rid52">52</a>]. Although clinicians often treat postabortal atony similar to postpartum atony, the second-trimester uterus has fewer <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> receptors, limiting response to high-dose oxytocin. Carboprost 250 mcg intramuscularly every 15 minutes up to eight doses and low-dose cervical <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> have both been described in the setting of postabortal hemorrhage [<a href="#rid53">53</a>]. Balloon tamponade with intrauterine balloon catheters, uterine compression sutures, and angiographic embolization might become necessary in more severe cases of hemorrhage [<a href="#rid54">54-56</a>]. Intractable hemorrhage refractory to other therapy can require hysterectomy.</p><p class="headingAnchor" id="H8857976"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>Meaningful mortality data, stratified according to induction regimen used, are unavailable. Given a very low number of deaths reported annually for all second-trimester abortions, it is unlikely that any commonly used medical regimen confers a significant risk of maternal death.</p><p class="headingAnchor" id="H8857982"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Follow-up for second-trimester induction abortion, including contraception options and methods to suppress lactation, is the same as for surgical abortion and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Postprocedure considerations'</a> and  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p class="headingAnchor" id="H1209131"><span class="h1">SPECIAL CIRCUMSTANCES</span><span class="headingEndMark"> — </span>Management of patients with special issues of concern (eg, uterine anomalies, low-lying placenta, multiple gestation) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Special circumstances'</a>.)</p><p class="headingAnchor" id="H3540225986"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p class="headingAnchor" id="H8856997"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Second-trimester pregnancy termination may be performed with medication or surgery. Medical induction (also referred to as medication or medical abortion) is performed using solely medications and results in an intact fetus, which may be preferable for a patient in certain circumstances. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedure preparation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – The role of laboratory testing for hemoglobin or hematocrit, Rh typing (and administration of Rhogam to Rh-negative individuals), and chlamydia and/or gonorrhea are described in detail separately. (See <a class="local">'Laboratory testing'</a> above and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylactic antibiotics</strong> – Prophylactic antibiotics are <strong>not</strong> typically advised for second-trimester medication abortion. (See <a class="local">'Prophylactic antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osmotic dilators</strong> – Osmotic dilators do <strong>not</strong> facilitate second-trimester medical abortion. Some clinicians use osmotic dilators if there is a high likelihood of conversion of the procedure to a surgical uterine evacuation. (See <a class="local">'Cervical dilation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induced fetal demise</strong> – Feticidal injections are often given to prevent live birth. Another potential goal of induced fetal demise is to facilitate labor induction. (See <a class="local">'Induced fetal demise'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anesthesia</strong> – Patients undergoing induction termination can receive analgesia or anesthesia similar to that used for obstetric labor induction. Intermittent narcotic administration suffices for some patients, while others desire epidural anesthesia. (See <a class="local">'Anesthesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol</strong> – Protocols for induction abortion vary, and generally include a prostaglandin (PG), usually <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, with or without <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>. Prior protocols using hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (increased risk of hypernatremia, coagulopathy, and hemorrhage) and <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> (longer induction to abortion intervals, increased risk of hemorrhage and water intoxication) have been largely abandoned. (See <a class="local">'Protocol'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients undergoing second-trimester induction abortion, we suggest use of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> combined with <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> rather than misoprostol alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Use of mifepristone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An example of a protocol is (see <a class="local">'Medical society protocols'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a> 200 mg, administered orally, <strong>plus</strong>: </p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> 800 mcg, administered vaginally, followed by 400 mcg, administered vaginally or sublingually every three hours for up to a maximum of five doses.</p><p></p><p class="bulletIndent3"><strong>or</strong></p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">Misoprostol</a> 400 mcg, administered buccally every three hours for up to a maximum of five doses also may be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Potential complications of induction abortion include retained placenta, uterine rupture, cervical laceration, infection, or hemorrhage. (See <a class="local">'Outcome and complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Achilles SL, Reeves MF, Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception 2011; 83:295.</a></li><li><a class="nounderline abstract_t">Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72:358.</a></li><li><a class="nounderline abstract_t">Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 1996; 175:173.</a></li><li><a class="nounderline abstract_t">Anselem O, Jouannic JM, Winer N, et al. Cervical Dilators Used Concurrently With Misoprostol to Shorten Labor in Second-Trimester Termination of Pregnancy: A Randomized Controlled Trial. Obstet Gynecol 2022; 140:453.</a></li><li><a class="nounderline abstract_t">Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol 1999; 94:139.</a></li><li><a class="nounderline abstract_t">Kafrissen ME, Barke MW, Workman P, et al. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol 1983; 147:344.</a></li><li><a class="nounderline abstract_t">Kapp N, Todd CS, Yadgarova KT, et al. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2alpha analogue for second-trimester induction termination in Uzbekistan. Contraception 2007; 76:461.</a></li><li><a class="nounderline abstract_t">Elami-Suzin M, Freeman MD, Porat N, et al. Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2013; 122:815.</a></li><li><a class="nounderline abstract_t">Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol 2005; 193:1065.</a></li><li><a class="nounderline abstract_t">Owen J, Hauth JC. Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med 1999; 8:48.</a></li><li><a class="nounderline abstract_t">Chen QJ, Hou SP, Meads C, et al. Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review. Eur J Obstet Gynecol Reprod Biol 2011; 159:247.</a></li><li><a class="nounderline abstract_t">Andersen LF, Poulsen HK, Sørensen SS, et al. Termination of second trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic PGF2 alpha. A comparative study. Eur J Obstet Gynecol Reprod Biol 1989; 31:1.</a></li><li><a class="nounderline abstract_t">Cameron IT, Baird DT. The use of 16,16-dimethyl-trans delta 2 prostaglandin E1 methyl ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early second trimester. A comparison with extra-amniotic prostaglandin E2. Br J Obstet Gynaecol 1984; 91:1136.</a></li><li><a class="nounderline abstract_t">Su LL, Biswas A, Choolani M, et al. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol 2005; 193:1410.</a></li><li><a class="nounderline abstract_t">Blanchard K, Clark S, Winikoff B, et al. Misoprostol for women's health: a review. Obstet Gynecol 2002; 99:316.</a></li><li><a class="nounderline abstract_t">Nor Azlin MI, Abdullah HS, Zainul Rashid MR, Jamil MA. Misoprostol (alone) in second trimester terminations of pregnancy: as effective as Gemeprost? J Obstet Gynaecol 2006; 26:546.</a></li><li><a class="nounderline abstract_t">Nuutila M, Toivonen J, Ylikorkala O, Halmesmäki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet Gynecol 1997; 90:896.</a></li><li><a class="nounderline abstract_t">Wong KS, Ngai CS, Wong AY, et al. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998; 58:207.</a></li><li><a class="nounderline abstract_t">Dodd JM, Crowther CA. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 2006; 125:3.</a></li><li><a class="nounderline abstract_t">Wildschut H, Both MI, Medema S, et al. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev 2011; :CD005216.</a></li><li><a class="nounderline abstract_t">Hammond C. Recent advances in second-trimester abortion: an evidence-based review. Am J Obstet Gynecol 2009; 200:347.</a></li><li><a class="nounderline abstract_t">Dickinson JE, Jennings BG, Doherty DA. Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2014; 123:1162.</a></li><li><a class="nounderline abstract_t">Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004; 69:51.</a></li><li><a class="nounderline abstract_t">Wong KS, Ngai CS, Yeo EL, et al. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000; 15:709.</a></li><li><a class="nounderline abstract_t">Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet 2004; 87:176.</a></li><li><a class="nounderline abstract_t">Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985; 32:45.</a></li><li><a class="nounderline abstract_t">Tang OS, Chan CC, Kan AS, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod 2005; 20:3062.</a></li><li><a class="nounderline abstract_t">Rose SB, Shand C, Simmons A. Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases. Aust N Z J Obstet Gynaecol 2006; 46:479.</a></li><li><a class="nounderline abstract_t">Allanson ER, Copson S, Spilsbury K, et al. Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial. Obstet Gynecol 2021; 137:801.</a></li><li><a class="nounderline abstract_t">Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. Contraception 2011; 84:4.</a></li><li><a class="nounderline abstract_t">Ngoc NT, Shochet T, Raghavan S, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2011; 118:601.</a></li><li><a class="nounderline abstract_t">Henkel A, Lerma K, Blumenthal PD, Shaw KA. Evaluation of shorter mifepristone to misoprostol intervals for second trimester medical abortion: a retrospective cohort study. Contraception 2020; 102:327.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol 2013; 121:1394. Reaffirmed 2023.</a></li><li class="breakAll">World Health Organization. Safe abortion: technical and policy guidance for health systems. World Health Organization, Geneva, Switzerland 2003.</li><li class="breakAll">Royal College of Obstetricians and Gynecologists. The care of women requesting induced abortion. Royal College of Obstetricians and Gynecologists, London 2004.</li><li><a class="nounderline abstract_t">Shaw KA, Topp NJ, Shaw JG, Blumenthal PD. Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review. Obstet Gynecol 2013; 121:1335.</a></li><li><a class="nounderline abstract_t">Abbas D, Ngoc N, Blum J, et al. Medical abortion with mifepristone and misoprostol at 13–22 weeks: how long between the mifepristone and the misoprostol? Contraception 2015; 91:428.</a></li><li><a class="nounderline abstract_t">Masse NM, Kuchta K, Plunkett BA, Ouyang DW. Complications associated with second trimester inductions of labor requiring greater than five doses of misoprostol. Contraception 2020; 101:53.</a></li><li><a class="nounderline abstract_t">Perritt JB, Burke A, Edelman AB. Interruption of nonviable pregnancies of 24-28 weeks' gestation using medical methods: release date June 2013 SFP guideline #20133. Contraception 2013; 88:341.</a></li><li><a class="nounderline abstract_t">Hou SP, Fang AH, Chen QF, et al. Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate (Rivanol®): a systematic review of Chinese trials. Contraception 2011; 84:214.</a></li><li><a class="nounderline abstract_t">Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol 2002; 187:393.</a></li><li><a class="nounderline abstract_t">Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol 2011; 117:788.</a></li><li><a class="nounderline abstract_t">Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation. Obstet Gynecol 2023; 142:330.</a></li><li><a class="nounderline abstract_t">Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006; 73:420.</a></li><li><a class="nounderline abstract_t">Castleman LD, Oanh KT, Hyman AG, et al. Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. Contraception 2006; 74:272.</a></li><li><a class="nounderline abstract_t">Whitley KA, Trinchere K, Prutsman W, et al. Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes. Am J Obstet Gynecol 2011; 205:386.e1.</a></li><li><a class="nounderline abstract_t">Berger GS, Kerenyi TD. Analysis of retained placenta associated with saline abortion: clinical considerations. Am J Obstet Gynecol 1974; 120:484.</a></li><li><a class="nounderline abstract_t">Kirz DS, Haag MK. Management of the third stage of labor in pregnancies terminated by prostaglandin E2. Am J Obstet Gynecol 1989; 160:412.</a></li><li><a class="nounderline abstract_t">Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76:310.</a></li><li><a class="nounderline abstract_t">Berghella V, Airoldi J, O'Neill AM, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. BJOG 2009; 116:1151.</a></li><li><a class="nounderline abstract_t">Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:1117.</a></li><li class="breakAll">Kapp N, von Hertzen H. Medical methods to induce abortion in the second trimester. In: Management of unintended and abnormal pregnancy: comprehensive abortion care, Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefied PG, Creinin MD (Eds), Wiley-Blackwell, Hoboken 2009. p.186.</li><li class="breakAll">Lichtenberg ES, Grimest DA. Surgical complications: Prevention and Management. In: Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care, Paul M, Lichtenberg ES, Borgatta L, et al (Eds), Wiley-Blackwell, Hoboken 2009. p.232.</li><li><a class="nounderline abstract_t">Baskett TF. Uterine compression sutures for postpartum hemorrhage: efficacy, morbidity, and subsequent pregnancy. Obstet Gynecol 2007; 110:68.</a></li><li><a class="nounderline abstract_t">Bakri YN, Amri A, Abdul Jabbar F. Tamponade-balloon for obstetrical bleeding. Int J Gynaecol Obstet 2001; 74:139.</a></li><li><a class="nounderline abstract_t">Steinauer JE, Diedrich JT, Wilson MW, et al. Uterine artery embolization in postabortion hemorrhage. Obstet Gynecol 2008; 111:881.</a></li></ol></div><div id="topicVersionRevision">Topic 90163 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397086" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246662" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694046" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926202" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cervical Dilators Used Concurrently With Misoprostol to Shorten Labor in Second-Trimester Termination of Pregnancy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10389735" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of causing fetal cardiac asystole on second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6624803" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Coagulopathy and induced abortion methods: rates and relative risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061705" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2alpha analogue for second-trimester induction termination in Uzbekistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084539" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mifepristone followed by misoprostol or oxytocin for second-trimester abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157113" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10090490" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741747" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2653893" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Termination of second trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic PGF2 alpha. A comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6594157" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The use of 16,16-dimethyl-trans delta 2 prostaglandin E1 methyl ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early second trimester. A comparison with extra-amniotic prostaglandin E2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202734" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11814515" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Misoprostol for women's health: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000504" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Misoprostol (alone) in second trimester terminations of pregnancy: as effective as Gemeprost?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397098" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9866000" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16466671" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249669" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Medical methods for mid-trimester termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318143" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recent advances in second-trimester abortion: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24807339" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14720621" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686224" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491575" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intravaginal misoprostol for pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4053605" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Progesterone receptor blockage. Effect on uterine contractility and early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16037110" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116051" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831935" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664506" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical guidelines. Labor induction abortion in the second trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860289" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592800" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluation of shorter mifepristone to misoprostol intervals for second trimester medical abortion: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812485" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ACOG Practice Bulletin No. 135: Second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812485" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : ACOG Practice Bulletin No. 135: Second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812485" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ACOG Practice Bulletin No. 135: Second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812471" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mifepristone-misoprostol dosing interval and effect on induction abortion times: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Medical abortion with mifepristone and misoprostol at 13–22 weeks: how long between the mifepristone and the misoprostol?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31655074" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complications associated with second trimester inductions of labor requiring greater than five doses of misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23756114" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interruption of nonviable pregnancies of 24-28 weeks' gestation using medical methods: release date June 2013 SFP guideline #20133.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21843683" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Termination of second-trimester pregnancy by mifepristone combined with misoprostol versus intra-amniotic injection of ethacridine lactate (Rivanol®): a systematic review of Chinese trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193931" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A comparison of medical induction and dilation and evacuation for second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422848" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37411022" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531179" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904423" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Introduction of the dilation and evacuation procedure for second-trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4547137" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Analysis of retained placenta associated with saline abortion: clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2916627" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of the third stage of labor in pregnancies terminated by prostaglandin E2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900443" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intervention rates for placental removal following induction abortion with misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438490" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384128" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384128" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384128" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601898" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Uterine compression sutures for postpartum hemorrhage: efficacy, morbidity, and subsequent pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502292" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Tamponade-balloon for obstetrical bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378747" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Uterine artery embolization in postabortion hemorrhage.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
